| Similar Articles |
|---|
 |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.   |
Chemistry World
June 19, 2013
Laura Howes |
AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city. |
Chemistry World
January 30, 2014
Phillip Broadwith |
AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India. |
Chemistry World
April 2, 2013
Bibiana Campos Seijo |
More job cuts... The news came in that AstraZeneca is to invest 330 million pounds in a new strategic R&D center and global headquarters in Cambridge, UK. Unfortunately, there is also a negative angle to this story. |
Chemistry World
March 19, 2013
Simon Hadlington |
Global AstraZeneca restructuring will cost 1600 jobs The company's global research blueprint will now be centered on the creation of three 'strategic R&D centers' for small molecules and biologics, to be based in Cambridge in the UK, Gaithersburg in Maryland, US, and Molndal in Sweden, to be completed by 2016. |
Chemistry World
February 2, 2012
Andrew Turley |
AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term. |
Chemistry World
April 3, 2014
Emma Stoye |
Pharma giants plan new public--private collaborations AstraZeneca will partner with the Medical Research Council, in its new Cambridge site, while the Wellcome Trust Genome Campus will host a new center for target validation studies, jointly founded with the European Bioinformatics Institute and GlaxoSmithKline. |
Chemistry World
May 28, 2014
Phillip Broadwith |
Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules. |
Chemistry World
May 19, 2014
Phillip Broadwith |
AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'. |
Chemistry World
October 1, 2015
Phillip Broadwith |
Human capital The wave of mergers and acquisitions -- particularly in the pharmaceutical sector, but also to some degree in fine and specialty chemicals -- highlights the growing importance of small and medium-sized enterprises in the business landscape. |
Chemistry World
March 2, 2015
Phillip Broadwith |
AstraZeneca to spin off anti-infectives research The new company's principal asset will be the novel gyrase inhibitor AZD0914, which is currently in Phase II clinical trials for treating gonorrhea. |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
The Motley Fool
November 23, 2004
Brian Gorman |
AstraZeneca Buys Into Cambridge Antibody Cambridge Antibody scored a new alliance, although the deal threatens to make it a house divided. |
Chemistry World
July 2010 |
Biotech - onwards and upwards The end of the UK's Eastern Region Biotechnology Initiative marks the beginning of a new era, writes Harriet Fear, former chief executive of Erbi |
The Motley Fool
May 15, 2006
Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note. |
Chemistry World
March 21, 2013
Phillip Broadwith |
AstraZeneca partners with Moderna for $240 million Moderna has developed a way to use messenger RNA (mRNA), the molecule cells use to turn DNA into proteins, to stimulate the production of specific proteins in cells where disease has diminished or eliminated their ability to do so. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
Chemistry World
November 9, 2015
Phillip Broadwith |
AstraZeneca to buy ZS Pharma for ion-balance drugs AstraZeneca has agreed to buy US specialist drug company ZS Pharma for around $2.7 billion in an effort to bolster its drug pipeline. |
Chemistry World
January 28, 2010
Nina Notman |
AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost. |
Chemistry World
April 21, 2009
Matt Wilkinson |
Survival of the fittest While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going. |
The Motley Fool
July 26, 2010
Tom Gardner |
A Disaster for Shareholders Two biotechnology stocks not worth the trouble. |
Chemistry World
March 22, 2012
Andrew Turley |
GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria. |
Chemistry World
July 15, 2008
Hepeng Jia |
Testing Times for New Liver Drug AstraZeneca is set to start clinical trials of a liver cancer drug developed for Chinese patients. |
Pharmaceutical Executive
June 1, 2013
Julian Upton |
Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property. |
The Motley Fool
December 20, 2004
Brian Gorman |
Cambridge Antibody's Underdog Story Cambridge Antibody's legal success against Abbott Laboratories is a sign of the biotech industry's continued maturation. Cambridge Antibody's stock rocketed 14% on the news of its win. |
Chemistry World
February 20, 2013
Laura Howes |
UK-India projects launched To coincide with the prime minister's visit to India, UK universities have announced a series of research partnerships and scholarships intended to boost the trade and education links between the UK and India. |
Chemistry World
July 31, 2014
Phillip Broadwith |
AstraZeneca stocks respiratory and cancer pipelines AstraZeneca has agreed to buy Spanish firm Almirall's respiratory drug assets for $875 million up front, plus up to $1.2 billion in performance milestone payments. |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
Chemistry World
May 2012 |
Biotech's bravura performer Bibiana Campos Seijo talks to scientist, philanthropist and serial entrepreneur Chris Evans, who is credited with having helped create the UK biotechnology industry. |
Chemistry World
December 5, 2013
Phillip Broadwith |
Merck KGaA snaps up electronic materials specialist The speciality chemicals arm of Merck KGaA has agreed to buy out AZ Electronic Materials for 1.6 billion pounds in cash. |
Search Engine Watch
February 27, 2008
Greg Jarboe |
Stop Press 2: Hitwise Data Shows Google News UK Unbiased Google News UK is free from both political and commercial influence and answers only to its users. |
Chemistry World
April 16, 2010
Sean Milmo |
Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK. |
Chemistry World
June 24, 2011
Andrew Turley |
Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK. |
National Real Estate Investor
June 1, 2003
H. Lee Murphy |
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry. |
Chemistry World
September 17, 2007 |
Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing. |
Chemistry World
March 20, 2008
Richard Van Noorden |
UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market. |
Chemistry World
August 3, 2015
Phillip Broadwith |
AstraZeneca sells off drugs to streamline portfolio Anglo-Swedish pharmaceutical firm AstraZeneca has agreed to sell the rights to two drugs that the company considers lie outside its strategic focus areas. |
Chemistry World
September 10, 2015
Matthew Gunther |
Research bodies urge UK government to protect science funding Nearly 200 research organizations have signed an open letter urging the UK government to protect science funding in the 2015 UK spending review. |
